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Introduction {#sec1}
============

In early normal lymphocyte development, gene segments that will eventually encode the immunoglobulin (Ig) and T cell receptor (TCR) variable regions are recombined from Variable (V), Diversity (D), and Joining (J) gene segments in a process known as V(D)J recombination ([@bib2]). During the DNA recognition and cleavage stage, recombination signal sequences (RSSs) that flank the individual V, D, and J gene segments are targets of RAG1/2 endonucleases and result in the generation of hair-pinned coding ends (CEs) and blunt-ended signal ends (SEs) ([@bib2], [@bib69]). In the second phase of V(D)J recombination, and-processing and end-ligation of CEs and SEs are mediated by classical non-homologous end-joining (C-NHEJ) factors and produce an imprecisely repaired coding joint (CJ) consisting of V(D)J exons and a precisely repaired but discarded circular signal joint (SJ) ([@bib2], [@bib69]). A set of core C-NHEJ factors (KU70, KU80, XRCC4, and LIG4) is absolutely essential for end-joining and is evolutionarily conserved ([@bib2], [@bib86]). Loss or defects of C-NHEJ factors can impair end-processing (DNA-PKCs, ARTEMIS) or end-joining (KU proteins, XRCC4, XLF, LIG4) and results in severe immunodeficiencies in both mouse models and human disease ([@bib2]; Kumar et al., 2014; [@bib4]). The DNA damage protein, ataxia telangiectasia mutated (ATM); its target, histone H2AX; and DNA damage response adaptor protein, MRI, are all also involved in the end-ligation process ([@bib10], [@bib79], [@bib40]). The single loss of any of these factors, or C-NHEJ factor XLF, has only modest effects on lymphogenesis and V(D)J recombination ([@bib10], [@bib79], [@bib40], [@bib52]). In addition to loss of the core C-NHEJ factors, combined deficiencies of proteins non-essential for the end-joining reaction can severely impair C-NHEJ to a similar extent, as in the case of combined loss of Xlf and Atm or Xlf and Mri ([@bib47], [@bib40], [@bib52], [@bib49], [@bib81]).

Another mammalian developmental process that utilizes C-NHEJ for repair of double-strand breaks (DSBs) is embryonic neurogenesis ([@bib27]). Neural progenitors that have exited the cell cycle and are migrating out of the embryonic ventricular zones as they differentiate are thought to rely on NHEJ-mediated repair of DSBs ([@bib27]). In mice, loss of core C-NHEJ factors leads to apoptosis of post-mitotic neurons and embryonic lethality ([@bib29], [@bib26], [@bib32]). Moreover, the same synthetic lethal combinations that result in severe lymphocyte developmental blocks (e.g., MRI and XLF) also display similar post-mitotic neuronal apoptosis ([@bib40], [@bib1]), indicating the critical role of end-ligation and C-NHEJ in the repair of DSBs during neurogenesis.

Histone H3 lysine-36 tri-methylation (H3K36me3) is a histone modification that is catalyzed by the non-redundant histone methyltransferase, *SETD2* ([@bib76]). H3K36me3 is associated with actively transcribed genes, and *SETD2* plays important roles in the control of gene expression ([@bib76]). Loss-of-function mutations in *SETD2* or dominant negative "onco-histone" mutations in the H3K36 residue itself have been described in a broad array of malignancies, particularly in hematopoietic and central nervous system (CNS) tumors ([@bib87], [@bib82], [@bib58], [@bib61], [@bib85], [@bib54]). In mammalian cells, *SETD2* regulates specific steps of the DNA damage response during mismatch repair (MMR) and homologous recombination (HR) ([@bib51], [@bib65], [@bib3]). More recently, a role for *Setd2* in normal thymocyte development and V(D)J recombination was described ([@bib45]). Although a role for H3K36 methylation in NHEJ had been previously suggested in yeast ([@bib24]), insights into the mechanism for how this post-translation histone modification in mammalian cells may impact this mode of repair remains unknown. Thus, to determine the role, if any, of *Setd2* and H3K36me3 in this mode of DNA repair in mammals, we studied its loss in two developmental pathways that utilize NHEJ. Here, we specifically show that whereas loss of *Setd2/*H3K36me3 does not completely abrogate repair of DSBs, loss leads to mis-repair in B-cell lymphoid development of Rag-induced DNA DSBs, especially when combined with loss of ATM kinase activity. Loss of *Setd2* leads to the increased formation of aberrant hybrid joints and additionally leads to reductions in overall B cell repertoire. Finally, loss of *Setd2* also leads to post-mitotic neuronal apoptosis.

Results {#sec2}
=======

Loss of *Setd2* Disrupts Normal Hematopoiesis, Particularly Lymphopoiesis {#sec2.1}
-------------------------------------------------------------------------

The complete loss of *Setd2* is embryonic lethal at embryonic day 10.5 (E10.5)--E11.5 ([@bib37]). Therefore, to study the role of *Setd2* in normal and malignant hematopoiesis, we previously generated a conditional mouse model expressing *Cre-*recombinase under inducible (*Mx1*) or constitutive (*Vav1*) hematopoietic lineage-restricted promoters ([@bib55]). The loss of *Setd2* ablated H3K36me3 in hematopoietic tissues through excision of exon 3 of *Setd2* ([Figure 1](#fig1){ref-type="fig"}A). Heterozygous mice had no overt hematopoietic phenotype ([Figures S1](#mmc1){ref-type="supplementary-material"}A, S1B and [S2](#mmc1){ref-type="supplementary-material"}D), whereas homozygous loss of *Setd2* resulted in a significant perturbation of normal hematopoiesis, including decreased overall bone marrow cellularity ([Figure 1](#fig1){ref-type="fig"}B), significant loss of mature lymphoid cells (B220^+^ B cells and CD3^+^ T cells) in the bone marrow, and expansion of erythroid (Ter119^+^) cells ([Figures 1](#fig1){ref-type="fig"}C and 1D). The significant reduction in T cells in the bone marrow observed upon complete *Setd2* loss was also mirrored by a severe diminution of thymic size ([Figure 1](#fig1){ref-type="fig"}E), which was concomitant with significant splenomegaly ([Figure 1](#fig1){ref-type="fig"}F). Strikingly, the splenomegaly was due to the aberrant expansion of erythroid cells and significant ablation of B-lymphoid (B220^+^) populations ([Figure 1](#fig1){ref-type="fig"}G). In addition, loss of *Setd2* induced qualitative and quantitative defects in hematopoietic stem cells, as well as abnormal erythroid progenitor expansion in the bone marrow ([Figures 1](#fig1){ref-type="fig"}D, 1G, 1H, [S1](#mmc1){ref-type="supplementary-material"}C--S1F, and [S2](#mmc1){ref-type="supplementary-material"}A--S2C). These hematopoietic phenotypes are consistent with other reports on *Setd2* knockout mice ([@bib84], [@bib83], [@bib45]). Altogether, these data indicate that loss of *Setd2* disrupts normal hematopoiesis and severely impacts lymphoid development.Figure 1Loss of *Setd2/*H3K36me3 Disrupts Normal Hematopoiesis and Severely Arrests Lymphoid Development(A) Western blot for H3K36me3, total H3, and Gapdh in bone marrow (BM), spleen (spl), and thymus (thy) of *Mx1/Vav1cre Setd2Δ/Δ* and *Setd2f/f* littermate controls.(B) Total cell count of whole bone marrow (n = 6 for all groups).(C) Ratio of *Mx1* and *Vav1 Setd2Δ/Δ* to controls of total cellularity of whole bone marrow (WBM), lineage-negative bone marrow cells (LIN^−^), B220^+^ B cells in bone marrow, and thymocytes (n = 15 for all groups).(D) Percent composition of differentiated hematopoietic cell populations in WBM, B cell (B220^+^), T cell (Cd3^+^), myeloid (Mac1^+^/Gr1^+^), and erythroid (Ter119^+^) (n=6 for all groups).(E) Thymic (n = 10) and (F) spleen (n = 100) weights for *Setd2Δ/Δ* and *Setd2f/f* littermate controls.(G) Percent composition of differentiated hematopoietic cell populations in spleen.(H) Total cellularity of LSK (Lin^−^Sca1^+^Kit^+^) and SLAM (LSK Cd150^+^Cd48^-^) hematopoietic stem populations (n = 6 for all groups).∗∗, p \< 0.01 ∗∗∗, p \< 0.001. See also [Figures S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"}.

*Setd2/*H3K36me3 Is Important in Normal Lymphocyte Development {#sec2.2}
--------------------------------------------------------------

We and others ([@bib84], [@bib83], [@bib45]) observed that loss of *Setd2* early in hematopoiesis resulted in significant depletions of the lymphoid populations in the bone marrow, spleen, and thymus ([Figures 1](#fig1){ref-type="fig"}C, 1D, 1G and [S1](#mmc1){ref-type="supplementary-material"}). To rule out that these early developmental deficiencies were not solely the result of reduced numbers of early lymphoid progenitors ([Figure S1](#mmc1){ref-type="supplementary-material"}C), we crossed our knockout mice with multiple B lymphoid lineage-restricted *Cre-*recombinase-expressing lines and found that whereas an early and profound proB block in development was only observed upon early deletion of *Setd2* (*Mx1, Vav1cre*) ([Figure 2](#fig2){ref-type="fig"}A), the deletion of *Setd2* in later stages of B cell development (with *hCD2, Mb1,* and *Cd19*cre) resulted in abnormal lymphocytic output that was more apparent in more mature B cell populations ([Figures 2](#fig2){ref-type="fig"}B and 2C). Specifically, loss of *Setd2* induced at later stages of B cell development significantly reduced detectable mature B cells (IgM^+^IgD^+^) in the bone marrow ([Figures 2](#fig2){ref-type="fig"}B and 2C) and resulted in the significant depletion of B cell lineage cells in the spleen ([Figure 2](#fig2){ref-type="fig"}C). These data suggest that *Setd2/*H3K36me3 is important in B lymphopoiesis at different stages, but that the severe block at the proB cell stage was only apparent with early loss in hematopoiesis.Figure 2*Setd2*/H3K36me3 Important for B Cell Development at Different Stages(A) Schematic of ontological expression of various B-lineage-restricted *cre*-recombinase mouse lines crossed to *Setd2f/f* mice with Igh locus rearrangement status indicated, and representative flow cytometry of B220^+^ early B cells progenitors (proB and preB cells) of control, *Vav/Mx1, hCD2, Cd19, and Mb1cre Setd2Δ/Δ* mice.(B) (i) Representative flow cytometry of bone marrow stained for early B cell progenitors and mature and immature B cell markers (IgM and IgD). (ii) Total bone marrow cellularity. (iii) Fraction composition of B220^+^, proB (B220^+^Cd43^+^IgM^−^), preB (B220^+^Cd43^+^IgM^−^), immature B (B220^+^Cd43^+^IgM^+^), and mature B cell (B220^+^IgM^+^IgD^+^) populations of *hCD2* (n = 7)*, Mb1* (n = 14)*, Cd19* (n = 9) *Setd2Δ/Δ,* and sex- and age-matched littermate controls.(C) Spleen (i) weight (n = 14 for all groups), (ii) total cellularity (n = 3 for all groups), and (iii) percentage composition of different B cell populations in bone marrow and spleen (n = 6 for all groups).Significance indicated as comparison with controls. ∗p \< 0.05, ∗∗p \< 0.01, ∗∗∗p \< 0.001, error bars represent SD.

*Setd2/*H3K36me3 Is Crucial for Normal Immunoglobulin Rearrangement in Early Lymphocyte Development Recombination {#sec2.3}
-----------------------------------------------------------------------------------------------------------------

The severe block in early B cell development was striking and warranted further examination. Early loss of *Setd2/*H3K36me3 blocked B cell development at the proB cell stage with similar total numbers of Fraction A (FrA)-defined pre-proB cells when compared with littermate controls ([Figures 3](#fig3){ref-type="fig"}A and [S3](#mmc1){ref-type="supplementary-material"}A--S3E). This block at the proB cell stage was concomitant with a near-complete ablation of immature IgM^+^ B cells in the bone marrow and spleen ([Figures 3](#fig3){ref-type="fig"}A and [S3](#mmc1){ref-type="supplementary-material"}B). Similarly, *Setd2Δ/Δ* mice exhibited a block in early T cell development at the double-negative stage (DN: CD4^−^CD8^-^), with an accumulation at the DN3 stage ([Figure 3](#fig3){ref-type="fig"}B). This arrest at the DN3 stage was similarly observed in *Mx1*-cre-driven exon 6-7 deletion *Setd2* knockout mouse ([@bib45]). Thus, lymphopoiesis in *Setd2Δ/Δ* mice appeared to be arrested at stages wherein V(D)J recombination occurs and is reminiscent of the lymphopenia observed with deficiency of factors necessary for V(D)J recombination ([@bib2]; Kumar et al., 2014; [@bib4]). In all early B/T cell progenitor populations of *Setd2Δ/Δ* mice, developmental blocks also coincided with increased levels of apoptosis and phospho-γH2ax ([Figures 3](#fig3){ref-type="fig"}C, [S3](#mmc1){ref-type="supplementary-material"}F, and S3G), despite similar *in vivo* proliferation rates and cell cycle status ([Figures 3](#fig3){ref-type="fig"}D and [S3](#mmc1){ref-type="supplementary-material"}H). Furthermore, *Setd2Δ/Δ* proB cells did not display any significant differences in the expression of factors related to V(D)J recombination at the gene or protein level ([Figures S4](#mmc1){ref-type="supplementary-material"}A--S4C). The arrest in B cell, but not in T cell, development in *Setd2Δ/Δ* mice could be partially rescued by crossing knockout mice with a transgenic mouse expressing a fully rearranged and productive immunoglobulin heavy chain (Igh) locus ([Figure 3](#fig3){ref-type="fig"}E), indicating a role for *Setd2*/H3K36me3 in enforcing normal V(D)J recombination.Figure 3Loss of *Setd2/*H3K36me3 Severely Arrests Lymphoid Development(A) Representative flow cytometry analysis of early B cell progenitors in B220^+^ bone marrow and total cellularity of B cell progenitor proportions of *Vav/Mx1cre Setd2Δ/Δ* and controls (n = 9).(B) Representative flow cytometric analysis of thymic cells, and total cellularity of thymic progenitor populations in *Setd2Δ/Δ* and *Setd2f/f* controls. DN: Cd4^-^Cd8^-^, DN1: DN Cd44^+^Cd25^-^; DN2: DN Cd44^+^Cd25^+^; DN3: DN Cd44^-^Cd25^+^ (n = 8).(C) Annexin V^+^ of B (n = 9) and T cell (n = 5) progenitor populations.(D) *In vivo* bromodeoxyuridine (BrdU) incorporation in early B and T cell progenitor compartments (n = 3). All values for BrdU were non-significant.(E) Representative immature B cell (B220^+^sIgM^+^) flow cytometric analysis and total cellularity of immature surface IgM^+^ population of bone marrow cells isolated from both legs and hips of *Setd2* mice crossed to mice transgenic for the Ig heavy chain complex (IgHelMD4) specific for hen egg lysozyme (HEL) (n = 4 for *Setd2f/f,* n = 5 for *Setd2Δ/Δ* MD4, and n = 3 for *Setd2Δ/Δ*).∗∗∗ p\<0.001, error bars represent SD. See also [Figures S3](#mmc1){ref-type="supplementary-material"} and [S4](#mmc1){ref-type="supplementary-material"}.

Loss of *Setd2*/H3K36me3 Does Not Abrogate Chromatin Architecture or Accessibility of the Early proB Igh Locus and Causes Aberrant V(D)J Recombination {#sec2.4}
------------------------------------------------------------------------------------------------------------------------------------------------------

To determine the impact of loss of *Setd2*/H3K36me3 on the Igh locus at the proB stage, we conducted chromatin immunoprecipitation (ChIP) sequencing and found both a global loss of H3K36me3 across the genome and a focal loss on the Igh locus where a well-studied critical regulatory region near the Eμ enhancer resides ([@bib16]) ([Figures 4](#fig4){ref-type="fig"}A and [S5](#mmc1){ref-type="supplementary-material"}A). As accessibility of this region is critical for B cell development ([@bib16], [@bib14]), we wanted to ascertain if the loss of H3K36me3 affected local chromatin architecture or accessibility. In proB cells, ablation of H3K36me3 neither affected chromatin accessibility ([Figures 4](#fig4){ref-type="fig"}B and [S5](#mmc1){ref-type="supplementary-material"}B) nor disrupted the local levels of H3K4me3 and H3K9ac ([Figure 4](#fig4){ref-type="fig"}C), two histone modifications essential for maintaining an open and actively transcribed chromatin structure at this regulatory region ([@bib16], [@bib14]) and for H3K4me3, the recruitment and activation of the Rag2 protein itself ([@bib72], [@bib43], [@bib44], [@bib56], [@bib7]). Loss of H3K36me3 did not significantly affect the methylation states of mono-, di-, or tri-methyl lysine-27 or mono- and di-methyl lysine-36 residues in this region ([Figure S5](#mmc1){ref-type="supplementary-material"}C). We detected equivalent recruitment of Rag1 and Hmgb2 to this same region on the Igh locus ([@bib72], [@bib43], [@bib44], [@bib56]) ([Figure 4](#fig4){ref-type="fig"}D), suggesting that the initiation phase of the V(D)J recombination reaction was intact. We were also not able to detect in sorted FrA proB cells any evidence of Rag1 recruitment or H3K36me3 at variable gene families on the Igh locus in either *Setd2*-deficient cells or controls ([Figure S5](#mmc1){ref-type="supplementary-material"}D). In addition, the level of sterile transcription of Igh genes was only mildly reduced ([Figure 4](#fig4){ref-type="fig"}E), particularly when compared with deletion of the Eμ enhancer, which causes significant transcriptional dysregulation ([@bib14]). Upon closer examination of recovered V(D)J recombination products from proB cells, we observed that *Setd2* deficiency resulted in aberrant recombination and, in some cases, lack of expected rearrangement products altogether ([Figures 4](#fig4){ref-type="fig"}F and [S5](#mmc1){ref-type="supplementary-material"}E). Combined, these data are suggestive that the V(D)J recombination defect is not due to decreased expression or regulation of the Igh locus, but due to defects in the repair phase of the reaction.Figure 4Loss of *Setd2*/H3K36me3 Does Not Alter Chromatin Architecture or Accessibility of the Early proB Igh Locus and Causes Abnormal V(D)J Recombination(A) H3K36me3 ChIP sequencing of the Igh locus of Cd19^−^/^+^ proB (B220^+^Cd43^+^IgM^−^) cells from bone marrow of *Vav Setd2Δ/Δ* and controls. (n = 3 for all groups). Magnification of region of Igh with focal H3K36me3; loss of representative H3K36me3 tracks overlaid with assay for transposase-accessible chromatin (ATAC)-seq of same region from control proB cells for reference. Annotation of critical regulatory sites as indicated.(B) Representative ATAC-seq tracks of regulatory region of the Igh locus described in (A) of sorted Cd19^-^ proB cells from two matched control and *Setd2* knockout sorted proB cells.(C) Representative ChIP-PCR of regulatory region for histone H3 marks K36me3, K9ac, and K4me3. Data representative of n = 3 independent experiments.(D) Representative ChIP-PCR of Rag1 and Hmgb2 of proB cells from *Setd2Δ/Δ* and controls at the same regulatory region with standard deviations as indicated, n = 3 independent experiments.(E) Relative quantitation of sterile transcription of D~H~ genes, Cμ, and enhancer RNAs of proB cells from *Setd2Δ/Δ* and controls. Data represented as an average of three independent ChIP-PCRs from three independently sorted proB cell populations.(F) Schematic and representative results of PCR assay to detect V(D)J recombination products of rearrangement of the Igh locus of different V~H~ families of sorted proB cells from *Setd2Δ/Δ* (KO) and controls (WT). Empty and filled triangles represent primers. No product meant germline non-rearrangement. Image representative of n = 3 independent PCR experiments.Error bars represent SD. See also [Figure S5](#mmc1){ref-type="supplementary-material"}.

Aberrant End-Joining of Rag-Induced DSB with *Setd2*/H3K36me3 Deficiency {#sec2.5}
------------------------------------------------------------------------

To ascertain if defects in *Setd2*-deficient lymphogenesis could be a consequence of impaired Rag-induced DSB repair during V(D)J recombination, we generated murine *Setd2-*deficient (*Setd2*^*−/−*^), *Ku80*^*−/−*^ (*Xrcc5*^*−/−*^), *and Lig4* ^*−/−*^ late-proB v-Abelson (v-Abl)-transformed lines expressing a *Bcl2* transgene by CRISPR/Cas9-mediated inactivation ([Figures S6](#mmc1){ref-type="supplementary-material"}A--S6D) ([@bib40], [@bib42]). Loss of *Setd2* in v-Abl cells neither perturbed the expression of factors involved in V(D)J recombination nor affected the cell cycle distribution of these cells ([Figures S7](#mmc1){ref-type="supplementary-material"}A--S7C) *in vitro*. Treatment with Abl kinase inhibitor imatinib (STI) induces G1 cell-cycle arrest and *Rag1/2* expression leading to κ light chain rearrangement ([@bib40], [@bib42]) ([Figure S8](#mmc1){ref-type="supplementary-material"}A). We additionally introduced a chromosomally integrated inversion recombination substrate (pMG-INV), which can be used to assess the efficiency of V(D)J recombination by measuring GFP expression in cells and/or visualization of the repair products and intermediates by Southern blotting and PCR-based strategies ([@bib40]) ([Figure 5](#fig5){ref-type="fig"}A). Inactivation of ATM kinase activity with an inhibitor (ATMi) is sufficient to induce the formation of hybrid joints (HJs, joining of CEs to SEs) ([@bib10]) and could additionally be used to observe aberrant V(D)J recombination.Figure 5Aberrant End-Joining of Rag-Induced DSB with *Setd2*/H3K36me3 Deficiency(A) Schematic of recombination substrate pMG-INV. Unrearranged (UR) and SE and CE intermediates and resulting SJs and CJs. Long-terminal repeats (LTRs), *XbaI* and *NheI* restriction digestion sites, recombination signal sequences (RSSs), GFP, *Thy1.2* cDNA, and corresponding probes shown.(B) Representative flow cytometric analysis of GFP expression in control and *Setd2*^−/−^ pMG-INV v-Abl cells treated with Abl kinase inhibitor imatinib (STI-571) and ATM kinase inhibitor (ATMi, KU55933) for 48 and 96 h.(C) GFP expression of pMG-INV harboring v-Abl cell lines treated for 72 h with imatinib ± ATMi assessed by flow cytometry. Control, *Lig4*^−/−^, and at least four independently derived *Xrcc5*^−/−^ and *Setd2*^−/−^ v-Abl clones were treated in n = 4 independent induction experiments. Significance to controls to STI-571 treatment alone condition was calculated. ∗∗∗p \< 0.001, error bars represent SD.(D) Southern blot analysis of genomic DNA from induced *Setd2*^−/−^ and control lines that were digested with (i and ii) XbaI and (iii) NheI hybridized with (i and iii) Thy1 or (ii) GFP probe. Hybrid Joins (HJ) indicated as well (joint of CEs and SEs).(E) Schematic of PCR method to detect the formation of a coding joint and hybrid joint recombination product of the pMG-INV retroviral recombination substrate, and PCR result of pMG-INV coding and hybrid joints from indicated v-Abl cell clones treated for 72 h with ABLki with or without ATMki (KU55933). *Il-2* gene PCR was used as a loading control. Blue arrow indicates coding joint product, and red arrow indicates hybrid joint product.(F) PCR strategy to detect endogenous Vκ6-23 to Jκ1 coding joints (CJ) and hybrid joints (HJ) in (i) control and *Setd2*-deficient v-Abl lines treated for 72 h with STI-571 ± ATMi and (ii) *Setd2f/f* and *Setd2Δ/Δ* splenocytes. *Il-2* gene PCR was used as a loading control and analyzed and quantified by high-sensitivity TapeStation (D1000). Blue arrow indicates CJ product, and red arrow indicates HJ product.See also [Figures S6--S9](#mmc1){ref-type="supplementary-material"}.

Comparable rearrangement efficiency of the pMG-INV substrate was observed in both wild-type (WT) and *Setd2*^*−/−*^ v-Abl cells treated with imatinib, as indicated by GFP expression ([Figure 5](#fig5){ref-type="fig"}B). As expected, treatment of WT v-Abl cells with ATMi resulted in a modest (25%) decrement in GFP expression ([Figure 5](#fig5){ref-type="fig"}B). Strikingly, treatment of *Setd2*^*−/−*^ cell lines with ATMi resulted in a ∼60% reduction in GFP expression ([Figure 5](#fig5){ref-type="fig"}C). This finding is reminiscent of the severe defect in GFP expression found in Xlf-deficient v-Abl cells treated with ATMi ([@bib81], [@bib49]) and suggests a functional redundancy between *Setd2*/H3K36me3 and Atm kinase activity in ensuring proper repair. To investigate potential effects on repair, we conducted Southern blotting, which revealed pMG-INV SJ and CJ formation without obvious accumulation of free unrepaired SEs and CEs in STI-treated WT and *Setd2*^*−/−*^ v-Abl B cells ([Figures 5](#fig5){ref-type="fig"}D and [S8](#mmc1){ref-type="supplementary-material"}B). Thus, like *Xlf*, *Mri*, and *Atm*, *Setd2* is not essential for C-NHEJ during V(D)J recombination ([@bib10], [@bib81], [@bib40]). The non-essentiality of *Setd2*/H3K36me3 for end-joining was further intimated by the inability of dual loss of *Setd2*/H3K36me3 and *p53* to generate translocations leading to the development of proB-cell lymphomas ([Figures S9](#mmc1){ref-type="supplementary-material"}A and S9B), unlike loss of core C-NHEJ factors in a *p53*-null background ([@bib21], [@bib30], [@bib26]).

Despite not being required for end-joining, ATMi-treated *Setd2*^*−/−*^ v-Abl cells exhibited significantly increased mis-repaired recombination products that corresponded to either repaired SJs but unrepaired CEs (SJ + CE) ([Figures 5](#fig5){ref-type="fig"}A, 5D(i-ii), and [S8](#mmc1){ref-type="supplementary-material"}B) or the formation of hybrid joins ([Figures 5](#fig5){ref-type="fig"}A, 5D(i), and [S8](#mmc1){ref-type="supplementary-material"}B), products consistent with the observed loss of GFP signal. The enhanced formation of HJs with loss of Atm kinase activity and *Setd2* was further corroborated by the increased detection of aberrant HJ products of the pMG-INV substrate in ATMi-treated *Setd2*^−/−^ cells ([Figure 5](#fig5){ref-type="fig"}E). Although we could detect evidence of HJ formation by PCR of the recombination substrate in *Setd2*^*−/−*^ lines without ATMi ([Figure 5](#fig5){ref-type="fig"}E), these products were below detection by Southern blotting ([Figures 5](#fig5){ref-type="fig"}D(i) and [S8](#mmc1){ref-type="supplementary-material"}B), but consistent with the modest decrease in GFP signal with STI treatment alone ([Figures 5](#fig5){ref-type="fig"}B and 5C). Furthermore, we could detect HJ formation not only from the endogenous κ light chain locus of v-Abl *Setd2* knockout cells but also in *Setd2Δ/Δ* splenocytes ([Figure 5](#fig5){ref-type="fig"}F). Together, these data indicate a novel role for *Setd2*/H3K36me3, especially in combination with Atm kinase activity, in the repair phase of V(D)J recombination to ensure proper joining.

Loss of *Setd2*/H3K36me3 Reduces Overall B Cell Repertoire {#sec2.6}
----------------------------------------------------------

Even without loss of Atm kinase activity, however, there was abundant evidence of aberrant and abnormal rearrangement of the endogenous Igh locus in primary *Setd2Δ/Δ* proB cells ([Figures 4](#fig4){ref-type="fig"}F and [S5](#mmc1){ref-type="supplementary-material"}E). We sequenced a similarly sized recombination product, present in both control and *Setd2Δ/Δ* proB cells, for three different heavy chain Variable gene families joined to the J~H~4 fragment and found additional abnormalities ([Figure 6](#fig6){ref-type="fig"}A). Loss of *Setd2*/H3K36me3 not only reduced the overall number of unique productive Igh rearrangements (assessed by the number of unique hypervariable complementarity defining region-3 \[CDR3\]) but also resulted in shortening of CDR3 length and reductions in N-nucleotide additions ([Figures 6](#fig6){ref-type="fig"}A and 6B) ([@bib9]). Similarly, when we looked at RNA-based transcripts of productive rearrangements of the Igh locus in proB cells using the hypervariable region calling algorithm TRUST ([@bib50], [@bib38], [@bib39]), *Setd2Δ/Δ* proB cells exhibited significant decreases in detectable unique CDR3 sequences and an overall decrease in overall B cell repertoire diversity ([Figures 6](#fig6){ref-type="fig"}C and 6D). Furthermore, global variable and joining gene usage was reduced ([Figure 6](#fig6){ref-type="fig"}E) in proB cells from *Setd2Δ/Δ* mice and coincided with evidence of increased clonality in variable gene usage, which did not appear to be dependent on the proximity to the Diversity and Joining gene segment regions on the Igh locus ([Figure 6](#fig6){ref-type="fig"}F). These observations indicate that, in addition to its role with Atm during end-joining to ensure appropriate repair, *Setd2*/H3K36me3 is also involved in other mechanisms that prevent mis-processing and mis-repair of broken DNA ends to ensure the fidelity of V(D)J recombination and is critical in maintaining a normal immune repertoire.Figure 6Loss of *Setd2*/H3K36me3 Reduces CDR3 Repertoire and Variable Gene Usage in proB Cells(A) PCR and next-generation sequencing (NGS) strategy of V(D)J recombination products of V~H~ families to J~H~4; 500-bp product (blue box) was extracted and submitted for NGS amplicon sequencing. Sequencing was analyzed with MiXCR T/B cell repertoire software ([@bib9]).(B) (i) Number of unique CDR3 clones, (ii) fraction and total clone counts by amino acid length, (iii) number of N-nucleotide additions, (iv) total nucleotide deletions of CDR3s recovered, and (v) total sequencing reads of *Setd2Δ/Δ* (KO) and controls for each V~H~ family. proB cells were sorted from n = 4 for each genotype and subjected to NGS analysis. Significance measured by Wilcoxon rank-sum test.RNA sequencing analysis of four independently sorted control and four *Setd2Δ/Δ* proB cell compartments was also conducted, and *de novo* assembly of CDR3 sequences was conducted using the TRUST algorithm ([@bib38], [@bib39], [@bib50]). (C) Unique CDR3 counts for heavy and light chain Ig loci from TRUST analysis.(D) Estimated B cell fraction of reads and B cell diversity recovered from analysis of RNA transcripts from TRUST analysis. Estimate B cell fraction was calculated by taking the fraction of number of reads mapped to BCR(IGV/IGJ/IGC) region to total read count. B cell diversity was calculated by determining the ratio of unique CDR3 count over the total number of reads mapped to BCR region.(E) Variable (V) and Joining (J) gene usage for (i) heavy chain and (ii) kappa light chain from TRUST analysis. Boxplots with SD.(F) Clonality of CDR3s plotted as a fraction of total reads and ordered by individual Variable gene families and distance from Diversity (D) and Joining gene loci from most proximal to most distal from right to left from TRUST analysis. Relative size of clone indicated by size of dot.

*Setd2*/H3K36me3 Prevents Post-mitotic Neuronal Apoptosis and Perinatal Lethality {#sec2.7}
---------------------------------------------------------------------------------

As *Setd2*/H3K36me3 seemed to be important for V(D)J recombination, we next wondered if it could play a role in Rag-independent C-NHEJ repair. To first test this, we assessed the sensitivity of asynchronous WT and *Setd2*^*−/−*^ v-Abl cells to ionizing radiation and found that *Setd2*^−/−^ v-Abl lines were more sensitive to DSBs induced by ionizing radiation ([Figure 7](#fig7){ref-type="fig"}A(i)). This increased sensitivity to ionizing radiation of *Setd2*-deficient cells, at levels even greater than that of core NHEJ factors *Xrcc5* (*Ku80*) and *Lig4* ([Figure 7](#fig7){ref-type="fig"}A(i) and [Figure S10](#mmc1){ref-type="supplementary-material"}A), could be in part due to previously described roles in HR-mediated DSB repair ascribed to *Setd2*/H3K36me3 ([@bib51], [@bib65], [@bib3]). To exclude the effects that may be driven by cells that may be cycling, we chose to study the sensitivity of G1-arrested v-Abl cells by inhibition with STI-571 or the Cdk4/6 inhibitor PD0332991 for 48 h before exposure to ionizing radiation. In both cell-cycle-arresting conditions, G1-arrested *Setd2*^−/−^ v-Abl cells exhibited increased sensitivity cells to DSBs induced by ionizing radiation compared with WT controls ([Figures 7](#fig7){ref-type="fig"}A(ii), [S10](#mmc1){ref-type="supplementary-material"}B, and S10C). Together, these data suggest that *Setd2*/H3K36me3 is important in the DSB repair in the G1 phase of cell cycle.Figure 7Post-mitotic Neuronal Apoptosis and Perinatal Lethality with Loss of *Setd2*/H3K36me3(A) (i) Asynchronous and (ii) STI-571 G1-arrested WT, *Xrcc5,* and two different *Setd2*^*−/−*^ v-Abl cells subjected to different doses of ionizing radiation and serially diluted five times in triplicate to assess survival. Values plotted as a mean of each dose as a percent of non-irradiated controls; bars represent standard deviation. Data are representative for three different independent treatment experiments. Viability was assessed at 72 h. No viable cells were detected beyond the 0.5 Gy dose for G1-arrested *Xrcc5* v-Abl clones.(B) Expected and observed genotype distributions of matings between *Nestin-cre Setd2Δ/+* mice to *Setd2f/+* mice (n = 15 litters) and *Nestin-cre Setd2Δ/+* mice to *Setd2f/f* mice (n = 16 litters) 21 days post-partum (dpp).(C) Embryo genotypes at different embryonic stages (n = 5 litters for each stage).(D) Litter sizes of E14.5, E16.5, E18.5, and 0.25 dpp from *Nestin-cre Setd2Δ/+* mice to *Setd2f/f* breedings. Significance to 0.25 dpp was measured (n = 5 litters for each stage except 0.25 dpp, n = 11).(E) Cleaved caspase 3 immunohistochemistry of E18.5 embryos. Sagittal sections show staining of regions of the diencephalic, telencephalic, and mesencephalic regions with magnifications indicated by corresponding colored boxes.(F) TUNEL assay of 2-h post-partum control and *Nestin-cre Setd2Δ/Δ* pups. Coronal sections of the lateral ventricle with magnifications indicated by corresponding red and green boxes.∗∗p \< 0.01 ∗∗∗p \< 0.001, error bars represent SD. See also [Figures S10](#mmc1){ref-type="supplementary-material"} and [S11](#mmc1){ref-type="supplementary-material"}.

In addition to lymphogenesis, core C-NHEJ factors are critical for enforcing normal neurogenesis, where differentiating post-mitotic neurons migrating out of the ventricular zone do not have HR available for repair of DNA DSBs and instead rely on C-NHEJ ([@bib27]). Given our findings for a role for *Setd2*/H3K36me3 in the repair phase of V(D)J recombination, we tested its potential functions in neurogenesis. Consistent with the defective CNS development and embryonic lethality observed in knockout mouse models of core C-NHEJ factors ([@bib29], [@bib26], [@bib32]), we observed post-mitotic neuronal apoptosis and perinatal lethality in mice with homozygous deletion of *Setd2* in neural progenitor-restricted *Nestin-cre*-expressing mice, where deletion has been demonstrated to occur before post-mitotic neurogenesis ([@bib53]). The severity of this phenotype is demonstrated by the complete absence of *Nestin-cre Setd2Δ/Δ* pups at 21 days post-partum (dpp) ([Figures 7](#fig7){ref-type="fig"}B and 7C) with perinatal lethality by 0.25 dpp ([Figure 7](#fig7){ref-type="fig"}D). Histopathological analysis of embryos revealed evidence of apoptosis of post-mitotic neurons as early as E14.5 ([Figures S11](#mmc1){ref-type="supplementary-material"}A and S11B), as well as more widespread apoptosis in the developing brain in E18.5 embryos and in 2-h post-partum pups ([Figures 7](#fig7){ref-type="fig"}E, 7F, [S11](#mmc1){ref-type="supplementary-material"}C, and S11D) suggesting a role for *Setd2*/H3K36me3 in embryonic neurogenesis that is reminiscent of deficiency for C-NHEJ factors.

Discussion {#sec3}
==========

The preservation of a genome is predicated on proper repair of DNA DSB and a balance between HR, which is a highly accurate and also slower form of repair that is restricted to the availability of a sister chromatid strand, and NHEJ, which is highly efficient but intrinsically error prone ([@bib74]). Although there have been some studies highlighting the importance of chromatin accessibility, nucleosome positioning, DNA looping, and recognition of histone modifications (e.g., H3K4me3 by RAG2) ([@bib72], [@bib43], [@bib7], [@bib57], [@bib56]) in the regulation of the V(D)J recombination process and phosphorylation of γH2AX in repair ([@bib79], [@bib13]), little has been described in terms of the impact of other chromatin modifications, especially in the end-joining phase of the V(D)J recombination reaction.

Here, we discovered a strong dependency of normal hematopoiesis and, in particular, lymphogenesis on *Setd2*/H3K36me3 phenotypes consistent with previously published reports of three distinctly engineered knockout mouse models ([@bib84], [@bib83], [@bib45]). Early loss of *Setd2*/H3K36me3 leads to severely impaired B and T cell development that could be partially rescued, in the case of B lymphogenesis, with the expression of a fully rearranged Igh locus, pointing to a role for *Setd2*/H3K36me3 in V(D)J recombination. This role of *Setd2* in V(D)J recombination is further corroborated by the partial rescue of T lymphopoiesis with the over-expression of a rearranged TCR in *Lck*-cre *Setd2Δ/Δ* mice ([@bib45]). Ji et al. also report decreased Rag1 occupancy across the Igh locus in B220^+^Cd19^+^ cells from *Cd19*cre *Setd2Δ/Δ* mice ([@bib45]), including at variable region family genes. In sorted proB cells (B220^+^Cd43^+^IgM^−^) where we induced loss of *Setd2*/H3K36me3 early in hematopoiesis, however, we could not detect a significant effect on the recruitment of Rag1 to the critical regulatory region near where the Eμ enhancer resides and where Rag1 has previously been shown to bind *in vivo* at the proB cell stage of development ([@bib44]). The observed Rag1 occupancy differences observed by [@bib45] in populations of lymphoid cells are likely impacted by their inclusion of more mature B cell populations (B220^+^Cd19^+^ includes Cd43^+^ late proB and more mature Cd43-preB cells) that are depleted in *Setd2Δ/Δ* mice, as well as by incomplete and leaky deletion of *Setd2* via the use *cre*-expressing mouse lines (C*d19cre*) that delete after the proB cell developmental stage of interest ([@bib67], [@bib35], [@bib46], [@bib71]).

We wanted to understand the nature of the defect in repair with early loss of *Setd2* in proB cells, especially with respect to end-ligation, as we could not detect significant differences in the initiation phase of V(D)J recombination and as we could detect recombination of the Igh locus, albeit abnormal recombination. We therefore turned to an inducible system to measure the repair defect and uncovered new roles for *Setd2*/H3K36me3 in the fidelity of the V(D)J recombination reaction, especially in combination with ATM kinase activity. We determined that *Setd2*/H3K36me3 is not absolutely required for end-ligation by the lack of detectable unrepaired CEs and SEs of an ectopically integrated recombination substrate, pMG-INV. This non-essentiality for repair is consistent with our ability to detect recombination products in proB cells of *Setd2Δ/Δ* mice, albeit abnormal ones, and the lack of proB lymphomas as a consequence of translocation events in dual *Setd2Δ/Δ p53Δ/Δ* mice. It is noteworthy that unlike dual loss of ATM and XLF, loss of *Setd2*/H3K36me3 and Atm kinase activity did not result in complete abolishment of proper end-joining, but did lead to increased abnormal joining (e.g., SJ + CE joins and HJs), suggesting that *Setd2*/H3K36me3\'s role in end-ligation is functionally distinct from C-NHEJ *XRCC4* paralogs *XLF* and *PAXX* ([@bib49], [@bib47]). Although we could detect robust and efficient conversion of fully and properly recombined SJ + CJ products of the pMG-INV recombination substrate in induced *Setd2*-deficient v-Abl cells, we could also detect, with combined loss of Atm kinase activity, an aberrant SJ + CE recombination product. This raises the possibility of a CE-specific hairpin opening/repair defect, which would certainly require further study as CEs are thought be efficiently processed and repaired at a much higher rate than SEs and CE-only defects have not previously been reported ([@bib66], [@bib70], [@bib68], [@bib12], [@bib60]).

Paradoxically, whereas the end-ligation defect of *Setd2*/H3K36me3 loss, as determined by the assessment of a recombination substrate in transformed v-Abl cells, may appear subtle, in mice, its loss severely arrests normal B/T lymphocyte development, similar to what is observed in mice with loss of C-NHEJ factors ([@bib2]; Kumar et al., 2014) and in contrast to loss of factors involved in end-ligation, such as Atm, Xlf, Paxx, or Mri individually ([@bib10], [@bib47], [@bib40], [@bib52], [@bib49], [@bib81]). This difference suggests that there are other determinants that contribute to the severe block in B (and T) lymphoid development in *Setd2* knockout mice. For example, certain factors present at the Igh locus in proB cells may not be fully recapitulated in the assessment of rearrangement of an ectopic recombination substrate in transformed v-Abl cells, potentially affecting both the efficiency and accuracy of repair.

Likewise, it is also possible that there are other roles of *ATM*, or *ATM* targets, and *SETD2* in end-joining that are not directly related and are mediated by distinct processes that, when combined, exacerbate mis-repair overall. Specifically, the loss of *Setd2*/H3K36me3 could influence the recruitment of factors associated with NHEJ in DNA DSB that recognize H3K36me3 (e.g., PHRF1 and PHF1) that could impact end-joining efficiency ([@bib15], [@bib36], [@bib62]), rather than playing a direct role in the stabilization of broken chromosomal ends, a function that has been ascribed to ATM ([@bib10]). Additionally, we did not find any overt gene expression differences in alternative-NHEJ (A-NHEJ) factors and were not able to detect higher rates of deletions or translocations thought to accompany some forms of this A-NHEJ ([@bib18]) in either our CDR3 repertoire analysis, products of recombination of the recombination substrate in v-Abl cells, or in mice with dual loss of *Setd2* and *p53.* These correlative lines of evidence however, do not fully preclude the possibility of rare forms of A-NHEJ contributing to the observed phenotype, warranting further investigation.

When we examined the abnormal recombination in proB cells of *Setd2Δ/Δ* mice more closely, we additionally noted significant loss of B cell repertoire and reduction of variable gene usage, characterized by less diversity in re-arranged, productive CDR3 sequences, as well as other abnormalities. Shortening of CDR3 length, without concomitant reduction of immune repertoire, has been previously connected to end-ligation factor, *XLF* ([@bib41]). In addition, shortening of CDR3 sequences of Ig heavy chain rearrangements has previously been observed in Pol X family knockouts (pol λ, μ), which with terminal deoxynucleotidyl transferase participates in nucleotide end-processing of heavy chain junctions during V(D)J recombination ([@bib6]). Thus, it is possible that *Setd2*/H3K36me3 may play additional roles in the end-processing of junctions, in addition to preventing the mis-repair in end-ligation we observed.

We also found that loss of *Setd2/*H3K36me3 increases sensitivity of cells to DSBs induced by ionizing radiation in both asynchronous and G1-arrested v-Abl cells, suggesting that *Setd2*/H3K36me3 may play a role in DSB repair activities in cells where HR would not be available, due to the lack of a sister chromatid. This result seemed to be supported by our discovery that neural-specific deletion of *Setd2*/H3K36me3 resulted in post-mitotic neuronal apoptosis. Although it is possible that other factors may be contributing to the neurogenesis defect, the temporal and spatial localization of apoptotic neuronal cells are highly suggestive of a role for *Setd2*/H3K36me3 in post-mitotic neurogenesis. The perinatal lethality we observed in *Nestin-cre Setd2Δ/Δ* mice is in stark contrast to *Nestin-cre*-driven conditional loss of core C-NHEJ factors, *Xrcc4* or *Lig4,* where mice survive to adulthood ([@bib28], [@bib78]). Instead, it parallels the severity of the developmental arrest we observed in lymphogenesis, despite *Setd2*/H3K36me3 not being essential for C-NHEJ repair.

Previous studies have indicated a role for H3K36me3 in not only the recruitment of components on DNA damage repair in both MMR (MSH2/6) ([@bib51]) and HR (CtIP) ([@bib65], [@bib3]) but also a role in a myriad of other cellular processes ([@bib76]). Although we have not exhaustively ruled out every potential role of *Setd2*/H3K36me3 in DSB repair, transcription, and splicing, we have attempted to study the role of *Setd2*/H3K36me3 in two systems that utilize NHEJ-mediated DSB repair by taking advantage of the non-redundancy of *Setd2* in two independent mammalian developmental processes. Given the high frequency of *SETD2* mutations in B and T cell lymphomas (Parker et al., 2016; [@bib82], [@bib58], [@bib61]), primary human immunodeficiency ([@bib45]), and neurological/developmental disorders (e.g., autism, intellectual disability, high-grade pediatric glioma) ([@bib25], [@bib20], [@bib75], [@bib48]), our findings demonstrating a role of *Setd2*/H3K36me3 in normal lymphogenesis and neurogenesis are especially noteworthy.

Limitations of Studies {#sec3.1}
----------------------

Limitations of our studies include our inability to assess localization of critical NHEJ factors (e.g., Rag2, Ku70, Ku80, Xrcc4, Lig4, and others) due to the lack of readily available antibodies to perform ChIP of these proteins. In addition, although the use of v-Abl-transformed late-proB cell lines with an ectopically expressed recombination substrate can determine the essentiality of factors for end-joining in NHEJ, the use of such a system fails to recapitulate the factors or genomic structure present at the endogenous immunoglobulin loci, which may also influence the V(D)J recombination process during early lymphocyte development. Thus, it is possible that the severity of the block in normal lymphocyte development observed *in vivo* could be influenced by factors and mechanisms beyond the role of *Setd2*/H3K36me3 in end-joining during the repair phase of V(D)J recombination. Also, we were unable to assess if there was a non-enzymatic role for the Setd2 protein itself in any of the NHEJ processes in lymphocyte development, as expression of a full-length Setd2 (∼2,500 amino acids, ∼8-kb nucleotide coding sequence) in primary murine cells was unable to be achieved (by us and also not reported by other groups with genetically engineered Setd2 knockout mouse models, including but limited to [@bib84], [@bib83], [@bib45]). We also did not fully and exhaustively investigate the role of A-NHEJ factors or the potential contribution of other roles that Setd2 and H3K36me3 play in normal cellular processes in both V(D)J recombination or post-mitotic neurogenesis settings.

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.

Data and Code Availability {#appsec1}
==========================

RNA-seq, ATAC-seq, ChIP-seq, TRUST, and MIXCR data generated and analyzed during the current study have been deposited into the National Center for Biotechnology Information (NCBI) Gene Expression Omnibus (GEO). The accession numbers for the RNA-seq, ATAC-seq, ChIP-seq, TRUST, and MIXCR data reported in this paper are [GSE130904](ncbi-geo:GSE130904){#intref0010}, [GSE131588](ncbi-geo:GSE131588){#intref0015}, [GSE131608](ncbi-geo:GSE131608){#intref0020}. These are unified under SuperSeries [GSE131690](ncbi-geo:GSE131690){#intref0025}.
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